"10.1371_journal.pone.0150569","plos one","2016-03-18T00:00:00Z","Tarik Asselah; Alex J Thompson; Robert Flisiak; Manuel Romero-Gomez; Diethelm Messinger; Georgios Bakalos; Mitchell L Shiffman","Centre de Recherche sur l’Inflammation (CRI), UMR 1149 Inserm, Université Paris Diderot, Service d’Hépatologie, AP-HP Hôpital Beaujon, Paris, France; Department of Gastroenterology, St Vincent’s Hospital, University of Melbourne, Melbourne, VIC, Australia; Department of Infectious Diseases and Hepatology, Medical University of Białystok, 15–540, Białystok, Poland; UCM Digestive Diseases and CIBERehd, Valme University Hospital, University of Seville, Seville, Spain; Biostatistics, PROMETRIS GmbH, 68219, Mannheim, Germany; Global Product Development Medical Affairs, F. Hoffmann-La Roche Ltd, 4074, Basel, Switzerland; Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport News, Richmond, VA, United States of America","Conceived and designed the experiments: TA MRG DM GB. Performed the experiments: RF DM. Analyzed the data: TA RF DM GB. Wrote the paper: TA AJT RF MRG DM GB MLS.","These studies were funded by F. Hoffmann-La Roche Ltd. T Asselah: speaker/consultant: Roche, Boehringer-Ingelheim, AbbVie, Achillion, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck. AJ Thompson: support by an NHMRC fellowship (1053344); consultant to Abbvie, Bristol-Myers Squibb, Gilead Sciences, Merck, Roche Diagnostics, Spring Bank Pharmaceuticals, Arrowhead; research support from Abbvie, Gilead Sciences, Merck; speaker for Abbvie, Bristol-Myers Squibb, Gilead Sciences and Merck. R Flisiak: a speaker and advisor to AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck, Novartis, Roche. M Romero-Gomez: consulting fees from AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck, Roche Farma, Ferrer, Boeringher Ingelgheim and Novartis; grant support from Roche, Merck and Gilead; and speaker fees from AbbVie, Gilead, Janssen, Merck, Roche Farma, Boeringher Ingelgheim, GSK. Diethelm Messinger is employed by PROMETRIS GmbH. PROMETRIS GmbH has a contract with F. Hoffmann La-Roche Ltd to provide statistical support. G Bakalos is employed by F. Hoffmann-La Roche Ltd. ML Shiffman: consulting fees from AbbVie, Achillion, Bristol-Myers Squibb, Gilead, Janssen, Merck, Roche/Genentech and Vertex; grant support from AbbVie, Achillion, Beckman-Colter, Bristol-Myers Squibb, Boehringer Ingelheim, Conatus, Gilead, Hologic, Intercept, Lumena and Novartis; and speaker fees from AbbVie, Bayer, Gilead, Janssen, Merck, Roche/Genentech and Vertex. Peginterferon alfa-2a (PEGASYS®) and ribavirin (COPEGUS®) are both products marketed by F. Hoffmann-La Roche, Basel, Switzerland and protected by various intellectual property rights. There are no other patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2016","03","Tarik Asselah","TA",7,TRUE,4,2,4,7,TRUE,TRUE,FALSE,0,NA,FALSE
